Cholesterol-lowering drug targets reduce risk of dementia: Mendelian randomization and meta-analyses of 1 million individuals.
Level 3 - non-randomized controlled study
Mendelian randomization and observational cohort meta-analysis
PubMed 41059729 · doi:10.1002/alz.70638
What was done
The authors evaluated whether genetically proxied non-high-density lipoprotein cholesterol (non-HDL-C) reduction via specific drug targets (HMGCR, NPC1L1, PCSK9, ANGPTL4, LPL, and CETP) reduces all-cause dementia risk. They analyzed data from 1,091,775 individuals across three prospective cohorts (individual-level data) and two consortia (summary-level data) using Cox regression alongside one- and two-sample Mendelian randomization, followed by meta-analysis.
What was found
Meta-analysis of one-sample Mendelian randomization odds ratios per 1 mmol/L (39 mg/dL) lower non-HDL-C was 0.24 (95% CI 0.18–0.31) for HMGCR, 0.18 (95% CI 0.12–0.25) for NPC1L1, 0.30 (95% CI 0.26–0.34) for CETP, 0.97 (95% CI 0.70–1.35) for PCSK9, 1.66 (95% CI 0.52–5.36) for ANGPTL4, and 1.41 (95% CI 0.63–3.16) for LPL. Cox regression and two-sample Mendelian randomization analyses yielded largely directionally consistent results.
Why it matters
This large-scale genetic analysis suggests that lifelong reduction of non-HDL cholesterol via the pathways targeted by statins (HMGCR), ezetimibe (NPC1L1), and CETP inhibitors substantially lowers dementia risk.
Limits
Mendelian randomization captures lifelong genetic variation, which may not directly equate to clinical interventions started later in life. Potential pleiotropy was not detailed in the abstract, and estimates for PCSK9, ANGPTL4, and LPL were imprecise with wide confidence intervals.
Cited by
- supports Individuals with loss-of-function mutations in PCSK9 and lifelong low LDL-C exhibit no increased incidence of cancer, neurodegenerative disease, or diabetes.